ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
+0.18 (3.01%)
At close: Apr 16, 2024, 4:00 PM
-0.05 (-0.81%)
After-hours: Apr 16, 2024, 7:56 PM EDT

Company Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.

pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.

The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.

ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.
ADMA Biologics logo
Country United States
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 624
CEO Adam S. Grossman

Contact Details

C/o Adma Biologics, Inc., 465 State Route 17
Ramsey, New Jersey 07446
United States
Phone (201) 478-5552

Stock Details

Ticker Symbol ADMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001368514
CUSIP Number 000899104
ISIN Number US0008991046
Employer ID 56-2590442
SIC Code 2836

Key Executives

Name Position
Adam S. Grossman Co-Founder, President, Chief Executive Officer and Director
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder and Vice Chairman of the Board
Brian Lenz CPA Executive Vice President, Chief Financial Officer and GM of ADMA BioCenters
Kaitlin Kestenberg Chief Operating Officer and Senior Vice President of Compliance
Drew Pantello Vice President of Marketing and Corporate Development
Cindy Petersen Executive Director of Human Resources
Skyler Bloom Senior Director of Business Development and Corporate Strategy

Latest SEC Filings

Date Type Title
Apr 15, 2024 ARS Filing
Apr 15, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 15, 2024 DEF 14A Other definitive proxy statements
Apr 2, 2024 8-K Current Report
Mar 13, 2024 144 Filing
Mar 11, 2024 8-K Current Report
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 5, 2024 8-K Current Report